{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:05:54Z","timestamp":1787947554179,"version":"build-2784847793"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","award":["Alnylam Pharmaceuticals"],"award-info":[{"award-number":["Alnylam Pharmaceuticals"]}],"id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hereditary transthyretin (ATTRv) amyloidosis is a rare, intractable genetic disorder caused by mutations in the transthyretin (<jats:italic>TTR<\/jats:italic>) gene. More than 150 <jats:italic>TTR<\/jats:italic> mutations have been identified, along with genotype-phenotype correlations. Early diagnosis is critical to facilitate the timely initiation of disease-modifying therapies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To characterize the genetic and clinical features of ATTRv amyloidosis at our referral center.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A total of 6,201 <jats:italic>TTR<\/jats:italic> genetic tests were conducted at Kumamoto University Hospital over a ten-year period and revealed 289 mutations, including 235 symptomatic cases, which were analyzed in this study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In a cohort of 235 patients with symptomatic ATTRv amyloidosis, 46 <jats:italic>TTR<\/jats:italic> mutations were identified. The genotypes were distributed as follows: V30M in endemic areas (7.7%), V30M in non-endemic areas (48.5%), and non-V30M mutations (43.8%). The mean age of onset was lowest for patients with V30M in endemic areas (42.4\u2009\u00b1\u200915.6 years) and higher for those with non-V30M mutations (60.6\u2009\u00b1\u200914.6 years) and V30M in non-endemic areas (64.5\u2009\u00b1\u200911.9 years). Family history was present in 93.3% of V30M cases in endemic areas but absent in 42.0% of V30M cases in non-endemic areas and 57.5% of non-V30M cases. Polyneuropathy was the predominant initial symptom, affecting 73.7% of endemic V30M cases, 54.3% of non-endemic V30M cases, and 34.6% of non-V30M cases. Diagnosis occurred earlier in patients with V30M in endemic areas than in other groups. Notably, delayed diagnosis has been observed in patients presenting with carpal tunnel syndrome or polyneuropathy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These findings demonstrate that patients with V30M in non-endemic areas and those with non-V30M mutations are more prevalent than previously recognized and that their genetic and clinical characteristics exhibit considerable diversity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-04006-6","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T12:23:45Z","timestamp":1756815825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Genetic and clinical features of hereditary transthyretin amyloidosis: a decade of experience at a Japanese referral center"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9657-5324","authenticated-orcid":false,"given":"Toshiya","family":"Nomura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Misumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Tasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konen","family":"Obayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuharu","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"4006_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","volume":"29","author":"Y Ando","year":"2022","unstructured":"Ando Y, Adams D, Benson MD, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022;29:143\u201355.","journal-title":"Amyloid"},{"issue":"3","key":"4006_CR2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/brain\/75.3.408","volume":"75","author":"C Andrade","year":"1952","unstructured":"Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952;75(3):408\u201327.","journal-title":"Brain"},{"issue":"6","key":"4006_CR3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/archneur.1968.00470360015001","volume":"18","author":"S Araki","year":"1968","unstructured":"Araki S, Mawatari S, Ohta M, et al. Polyneuritic amyloidosis in a Japanese family. Arch Neurol. 1968;18(6):593\u2013602.","journal-title":"Arch Neurol"},{"key":"4006_CR4","first-page":"1","volume":"590","author":"R Andersson","year":"1976","unstructured":"Andersson R. Familial amyloidosis with polyneuropathy. A clinical study based on patients living in Northern Sweden. Acta Med Scand Suppl. 1976;590:1\u201364.","journal-title":"Acta Med Scand Suppl"},{"issue":"3","key":"4006_CR5","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S0006-291X(83)80224-1","volume":"116","author":"S Tawara","year":"1983","unstructured":"Tawara S, Nakazato M, Kangawa K, et al. Identification of amyloid prealbumin variant in Familial amyloidotic polyneuropathy (Japanese type). Biochem Biophys Res Commun. 1983;116(3):880\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"4006_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00415-017-8640-7","volume":"265","author":"T Yamashita","year":"2018","unstructured":"Yamashita T, Ueda M, Misumi Y, et al. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan. J Neurol. 2018;265(1):134\u201340.","journal-title":"J Neurol"},{"key":"4006_CR7","unstructured":"Mutations in transthyretin gene (TTR). [Mutations in hereditary amyloidosis website]. Available at: http:\/\/amyloidosismutations.com\/mut-attr.php. Accessed November 27, 2024."},{"issue":"11","key":"4006_CR8","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/archneur.59.11.1771","volume":"59","author":"H Koike","year":"2002","unstructured":"Koike H, Misu K, Ikeda S, et al. Study group for hereditary neuropathy in japan. Type I (transthyretin Met30) Familial amyloid polyneuropathy in japan. early- vs late-onset form. Arch Neurol. 2002;59(11):1771\u20136.","journal-title":"Arch Neurol"},{"issue":"1","key":"4006_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/mus.20644","volume":"35","author":"I Concei\u00e7\u00e3o","year":"2007","unstructured":"Concei\u00e7\u00e3o I, De Carvalho M. Clinical variability in type I Familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve. 2007;35(1):116\u20138.","journal-title":"Muscle Nerve"},{"key":"4006_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/2047-9158-3-19","volume":"3","author":"M Ueda","year":"2014","unstructured":"Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener. 2014;3:19.","journal-title":"Transl Neurodegener"},{"issue":"2","key":"4006_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.23521","volume":"47","author":"MD Benson","year":"2013","unstructured":"Benson MD. Liver transplantation and transthyretin amyloidosis. Muscle Nerve. 2013;47(2):157\u201362.","journal-title":"Muscle Nerve"},{"issue":"9","key":"4006_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1212\/WNL.0b013e318248df18","volume":"78","author":"T Yamashita","year":"2012","unstructured":"Yamashita T, Ando Y, Okamoto S, et al. Long-term survival after liver transplantation in patients with Familial amyloid polyneuropathy. Neurology. 2012;78(9):637\u201343.","journal-title":"Neurology"},{"issue":"8","key":"4006_CR13","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin Familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785\u201392.","journal-title":"Neurology"},{"issue":"24","key":"4006_CR14","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk JL, Suhr OB, Obici L, et al. Diflunisal trial consortium. Repurposing diflunisal for Familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658\u201367.","journal-title":"JAMA"},{"issue":"1","key":"4006_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"4006_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS, et al. HELIOS-A collaborators. Efficacy and safety of Vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):1\u20139.","journal-title":"Amyloid"},{"issue":"1","key":"4006_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22\u201331.","journal-title":"N Engl J Med"},{"key":"4006_CR18","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","volume":"26","author":"S Dorbala","year":"2019","unstructured":"Dorbala S, Ando Y, Bokhari S, et al. ASNC\/AHA\/ASE\/EANM\/ HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26:2065\u2013123.","journal-title":"J Nucl Cardiol"},{"issue":"4","key":"4006_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/pin.12902","volume":"70","author":"H Naiki","year":"2020","unstructured":"Naiki H, Sekijima Y, Ueda M, et al. Human amyloidosis, still intractable but becoming curable: the essential role of pathological diagnosis in the selection of type-specific therapeutics. Pathol Int. 2020;70(4):191\u20138.","journal-title":"Pathol Int"},{"issue":"1","key":"4006_CR20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1212\/01.WNL.0000132966.36437.12","volume":"63","author":"H Koike","year":"2004","unstructured":"Koike H, Misu K, Sugiura M, et al. Pathology of early- vs late-onset TTR Met30 Familial amyloid polyneuropathy. Neurology. 2004;63(1):129\u201338.","journal-title":"Neurology"},{"issue":"4","key":"4006_CR21","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1136\/jmg.2003.014803","volume":"41","author":"H Ohmori","year":"2004","unstructured":"Ohmori H, Ando Y, Makita Y, et al. Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of Familial amyloidotic polyneuropathy. J Med Genet. 2004;41(4):e51.","journal-title":"J Med Genet"},{"issue":"9","key":"4006_CR22","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.1007\/s00415-024-12509-8","volume":"271","author":"E Carvalho","year":"2024","unstructured":"Carvalho E, Dias A, Coelho T, et al. Hereditary transthyretin amyloidosis: a myriad of factors that influence phenotypic variability. J Neurol. 2024;271(9):5746\u201361.","journal-title":"J Neurol"},{"key":"4006_CR23","doi-asserted-by":"publisher","first-page":"105313","DOI":"10.1016\/j.neuint.2022.105313","volume":"155","author":"M Ueda","year":"2022","unstructured":"Ueda M. Transthyretin: its function and amyloid formation. Neurochem Int. 2022;155:105313.","journal-title":"Neurochem Int"},{"issue":"1","key":"4006_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2005.01.018","volume":"121","author":"Y Sekijima","year":"2005","unstructured":"Sekijima Y, Wiseman RL, Matteson J, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell. 2005;121(1):73\u201385.","journal-title":"Cell"},{"issue":"1","key":"4006_CR25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13023-022-02359-w","volume":"18","author":"A Dispenzieri","year":"2022","unstructured":"Dispenzieri A, Coelho T, Concei\u00e7\u00e3o I, et al. THAOS investigators. Clinical and genetic profile of patients enrolled in the transthyretin amyloidosis outcomes survey (THAOS): 14-year update. Orphanet J Rare Dis. 2022;18(1):236.","journal-title":"Orphanet J Rare Dis"},{"key":"4006_CR26","doi-asserted-by":"publisher","first-page":"116813","DOI":"10.1016\/j.jns.2020.116813","volume":"414","author":"M Ueda","year":"2020","unstructured":"Ueda M, Sekijima Y, Koike H, et al. Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies. J Neurol Sci. 2020;414:116813.","journal-title":"J Neurol Sci"},{"issue":"7","key":"4006_CR27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1212\/01.wnl.0000267338.45673.f4","volume":"69","author":"V Plant\u00e9-Bordeneuve","year":"2007","unstructured":"Plant\u00e9-Bordeneuve V, Ferreira A, Lalu T, et al. Diagnostic pitfalls in sporadic transthyretin Familial amyloid polyneuropathy (TTR-FAP). Neurology. 2007;69(7):693\u20138.","journal-title":"Neurology"},{"issue":"5","key":"4006_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/jnnp-2016-315262","volume":"88","author":"A Cortese","year":"2017","unstructured":"Cortese A, Vegezzi E, Lozza A, et al. Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. J Neurol Neurosurg Psychiatry. 2017;88(5):457\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04006-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04006-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04006-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:28:04Z","timestamp":1757478484000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-04006-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4006"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04006-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were approved by the Human Ethics Review Committee of Kumamoto University (Approval Nos. 450 and 1916). Informed consent was obtained from all patients prior to their participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Drs. Misumi and Ando reported receiving grants from Alnylam and Pfizer outside the submitted work. Dr. Tasaki reported receiving grants from Pfizer outside the submitted work. Dr. Ueda reported receiving grants and personal fees from Alnylam and Pfizer outside the submitted work. No other disclosures were reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"474"}}